Michael A. Panzara - 18 Mar 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director
Signature
Glenna Mileson, Attorney-in-fact for Michael Panzara
Issuer symbol
ATHA
Transactions as of
18 Mar 2022
Net transactions value
$0
Form type
4
Filing time
21 Mar 2022, 16:40:34 UTC
Previous filing
18 Feb 2022
Next filing
06 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +27,742 $0.000000 27,742 18 Mar 2022 Common Stock 27,742 $10.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth of the shares subject to the option will vest on April 18, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter.